LivaNova
(Nasdaq: LIVN)
announced today that Marco Dolci intends to retire from his position as president of the cardiopulmonary business unit.
Dolci plans to retire by Dec. 31, 2023, continuing in his role to support the transition of responsibilities through the end of the year. The company appointed Franco Poletti to serve as interim GM of cardiopulmonary to support the transition. He’ll do so in addition to his current role as VP of cardiopulmonary for Europe, effective immediately.
The London-based medtech company plans to retain a leading international executive search firm to help find a permanent successor. It’s another high-profile executive departure for the company, which saw CEO Damien McDonald resign in April.
LivaNova noted Dolci’s role in the progress of its Essenz perfusion system, which just last month hit another regulatory milestone.
“On behalf of the board, the executive leadership team and the employees at LivaNova, I would like to thank Marco for his leadership over the last 6.5 years, especially during the development and launch of the Essenz perfusion system and during a challenging time of market and supply chain disruption during and post-pandemic,” said Bill Kozy, interim CEO and board chair. “We wish Marco the best in his retirement from LivaNova. We are confident in Franco and our experienced CP senior leadership team and expect a smooth transition.”
Poletti joined LivaNova, then Sorin Group, in 1991. He offers wide-ranging experience in commercial strategy and execution in the cardiopulmonary market. Poletti has led global and regional divisions of the CP business and has overseen various stages of product development and launches. He has also held leadership roles in the neuromodulation business unit while at LivaNova.